Why Is HIMS Stock Surging More Than 11% After-Hours Today?
Hims & Hers Health (HIMS) shares rose 14% during trading and 11% after-hours after the Trump administration considered easing rules on peptides. The FDA will review 12 peptides, potentially allowing compounding pharmacies to produce them. Hims expressed interest in peptides during its last earnings call. Analysts' average 12-month price target is $24, with most rating it 'Hold'.
How this was made
The 30-second read
Why it matters
The announcement directly benefits Hims & Hers Health, which has expressed interest in peptide offerings, driving a sharp after‑hours price jump.
Market read
Regulatory change creates immediate upside potential for HIMS and may affect the broader consumer health sector.
What to watch
Potential supply chain constraints and reimbursement uncertainties for peptide products.
Background
The FDA, prompted by the Health Secretary, is reevaluating peptide classifications, removing safety risk designations for 12 substances.
Ticker impact
Shares surged 11% after-hours as the FDA announced removal of 12 peptides from the high‑risk drug category, a regulatory change directly affecting Hims & Hers Health.
Potential further upside if the company launches peptide offerings.
The FDA move is a fresh catalyst; the stock already reacted strongly, indicating market optimism.
Market effects
May spur broader interest in peptide therapeutics across the telehealth and consumer health sector.
U.S. market sees heightened activity in biotech and consumer health stocks.
Regulatory shift could influence international regulators and peers in the peptide market.
Counterpoint
If FDA guidance tightens later, the initial enthusiasm could reverse, leading to a pullback.
Key entities
- CompanyHims & Hers Health
Telehealth company trading under ticker HIMS.
- RegulatorU.S. Food and Drug Administration
Agency removing peptides from high‑risk drug category.
